Clinical trial
A Randomized, Double-blind Study of the Effect of Treatment Duration and Dose of PEGASYS on HBeAg Seroconversion and Safety in Patients With HBeAg Positive Chronic Hepatitis B.
NCT00435825 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind Study of the Effect of Treatment Duration and Dose of PEGASYS on HBeAg Seroconversion and Safety in Patients With HBeAg Positive Chronic Hepatitis B.
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- March 31, 2007
- Completion date
- December 31, 2010
- Enrollment
- 551 (actual)
- Sites
- 55
Conditions
As the registry lists them; a condition with its own page is linked.